View Archive

Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

MBCC: Medical Crossfire®: Real World Scenarios and Applications for Biosimilars in HER2-Positive Breast Cancer: Key Concepts for Clinical Decision-Making

MBCC: Medical Crossfire®: Real World Scenarios and Applications for Biosimilars in HER2-Positive Breast Cancer: Key Concepts for Clinical Decision-Making

Saturday, March 7, 2020

Breakfast and Registration: 6:30 AM – 7:00 AM
Scientific Session: 7:00 AM – 8:30 AM

Fontainebleau Miami Beach
Meeting Room: Fontaine
4441 Collins Avenue
Miami Beach, FL 33140


HER2-directed therapies have been transforming breast cancer care for over 20 years in both adjuvant and metastatic settings. The recent approvals of 4 biosimilar monoclonal antibodies targeting HER2 now offer healthcare professionals an expansion of treatment choices, with increased access at reduced costs. However, due to the potential complexity of manufacturing biosimilars with fidelity to the reference product, HCPs may be concerned with the validation of comparable efficacy and safety of these formulations. HCPs need to familiarize themselves with the development process for biosimilars as well as the global differences in criteria for bioequivalence and interchangeability in order to interpret the clinical data and to confidently prescribe these biosimilar options for their patients.

Medical Crossfire®: Real World Scenarios and Applications for Biosimilars in HER2-Positive Breast Cancer: Key Concepts for Clinical Decision-Making is a CME-certified educational breakfast symposium ancillary to the 37th Annual Miami Breast Cancer Conference®. This program will cover global variations in key regulatory aspects of biosimilars, considerations for naming conventions, and the required scientific rigor necessary for the biosimilar development and approval process. Panelists will discuss clinical data supporting the use of biosimilars in breast cancer treatment and utilize case-based scenarios to contextualize best practices for incorporating biosimilars into clinical practice.

Benefits of Attending

  • Gain an appreciation for the variabilities that exist between origination biologic products and biosimilars, and for the stringency of biosimilar testing
  • Learn strategies to address patient questions and concerns regarding approved biosimilars, especially regarding comparative safety and efficacy data between biosimilars and reference biologics
  • Gain awareness of the clinical trials evaluating current and emerging biosimilars for breast cancer treatment that may affect your practice in the future

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Target Audience: HCPs Who Treat Breast Cancer

This educational activity is directed toward medical oncologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the comprehensive set of preclinical and clinical data required to demonstrate the comparability of a biosimilar with its reference product
  • Discuss clinical data supporting approved and emerging biosimilar agents in the treatment of HER2-positive breast cancer
  • Assess clinician concerns and challenges regarding efficacy and safety of biosimilars as they are integrated into clinical practice
  • List pharmacovigilance considerations for biosimilars in the U.S. and ensure familiarity with safety and efficacy data of biosimilar products.

Program Chair

Hope S. Rugo
Hope S. Rugo, MD, FASCO
Professor of Medicine
Director of Breast Oncology and Clinical Trials Education
University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center
San Francisco, CA


2 Ways to Register
  1. Online: Click here.
  2. Phone: Please call +1-(888)-949-0045 or +1-(609)-378-3701.
Physicians' Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

Meeting information is accurate at the time of posting.

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

In case of onsite emergency:

Professional Information


Calendar of Events
Filter By